$Zai Lab Ltd(ZLAB)$ I’ve been

$Zai Lab Ltd(ZLAB)$ I’ve been keeping an eye on Zai Lab for a while, and their ZL-1310 just stole the spotlight at ASCO! A bunch of Wall Street analysts are saying the data was way above expectations. Morgan Stanley even dropped a fresh report, and management shared more insights during the earnings call. Compared to its competitor Tarlatamab, ZL-1310 has a differentiated MoA and easier administration，if the data keeps looking good, its edge will only grow stronger.

Plus, the FDA didn’t object to its accelerated path as a monotherapy for 2L SCLC. A pivotal study is expected to kick off in the second half of 2025, with OS and ORR as primary endpoints. If that trial launches as planned, it’ll be a key catalyst for the stock. And don’t forget，by year-end, we’re expecting combo therapy data in 1L too. If that data pops up, it could be another major boost!

Winning Trades

Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":444211210699304,"tweetId":"444211210699304","gmtCreate":1749452468690,"gmtModify":1749455232112,"author":{"id":3479274781763777,"idStr":"3479274781763777","authorId":3479274781763777,"authorIdStr":"3479274781763777","name":"tothehill","avatar":"https://static.tigerbbs.com/d63237e21ae39bc54951c8ab6ec41ee9","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":50,"starInvestorFlag":false},"themes":[{"themeId":"7516f9ef7e8042739b8597466da26fe7","categoryId":"7cf744760f454845a1870a05ea4e151d","name":"Winning Trades","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":7516f9ef7e8042739b8597466da26fe7}&rnconfig={\"headerBarHidden\": true}","description":"Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.","image":"https://community-static.tradeup.com/news/14c89d9656aedb9a4698e7996c575947"}],"images":[{"img":"https://community-static.tradeup.com/news/6e183160ca6f9a065b5326132dab8599","width":"767","height":"1280"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/6e183160ca6f9a065b5326132dab8599","width":"767","height":"1280"}],"html":"<html><head></head><body> <a data-mention-id=\"ZLAB\" class=\"teditor-mention\" data-mention-name=\"Zai Lab Ltd\" href=\"https://ttm.financial/S/ZLAB\">$Zai Lab Ltd(ZLAB)$</a> I’ve been keeping an eye on Zai Lab for a while, and their ZL-1310 just stole the spotlight at ASCO! A bunch of Wall Street analysts are saying the data was way above expectations. Morgan Stanley even dropped a fresh report, and management shared more insights during the earnings call. Compared to its competitor Tarlatamab, ZL-1310 has a differentiated MoA and easier administration，if the data keeps looking good, its edge will only grow stronger. Plus, the FDA didn’t object to its accelerated path as a monotherapy for 2L SCLC. A pivotal study is expected to kick off in the second half of 2025, with OS and ORR as primary endpoints. If that trial launches as planned, it’ll be a key catalyst for the stock. And don’t forget，by year-end, we’re expecting combo therapy data in 1L too. If that data pops up, it could be another major boost!<img src=\"https://community-static.tradeup.com/news/6e183160ca6f9a065b5326132dab8599\" tg-width=\"767\" tg-height=\"1280\"></body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"ZLAB\" class=\"teditor-mention\" data-mention-name=\"Zai Lab Ltd\" href=\"https://ttm.financial/S/ZLAB\">$Zai Lab Ltd(ZLAB)$</a> I’ve been keeping an eye on Zai Lab for a while, and their ZL-1310 just stole the spotlight at ASCO! A bunch of Wall Street analysts are saying the data was way above expectations. Morgan Stanley even dropped a fresh report, and management shared more insights during the earnings call. Compared to its competitor Tarlatamab, ZL-1310 has a differentiated MoA and easier administration，if the data keeps looking good, its edge will only grow stronger. Plus, the FDA didn’t object to its accelerated path as a monotherapy for 2L SCLC. A pivotal study is expected to kick off in the second half of 2025, with OS and ORR as primary endpoints. If that trial launches as planned, it’ll be a key catalyst for the stock. And don’t forget，by year-end, we’re expecting combo therapy data in 1L too. If that data pops up, it could be another major boost!<img src=\"https://community-static.tradeup.com/news/6e183160ca6f9a065b5326132dab8599\" tg-width=\"767\" tg-height=\"1280\"></body></html>","text":"$Zai Lab Ltd(ZLAB)$ I’ve been keeping an eye on Zai Lab for a while, and their ZL-1310 just stole the spotlight at ASCO! A bunch of Wall Street analysts are saying the data was way above expectations. Morgan Stanley even dropped a fresh report, and management shared more insights during the earnings call. Compared to its competitor Tarlatamab, ZL-1310 has a differentiated MoA and easier administration，if the data keeps looking good, its edge will only grow stronger. Plus, the FDA didn’t object to its accelerated path as a monotherapy for 2L SCLC. A pivotal study is expected to kick off in the second half of 2025, with OS and ORR as primary endpoints. If that trial launches as planned, it’ll be a key catalyst for the stock. And don’t forget，by year-end, we’re expecting combo therapy data in 1L too. If that data pops up, it could be another major boost!","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/444211210699304","repostId":0,"isVote":1,"tweetType":1,"viewCount":1497,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ZLAB"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":714,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/444211210699304"}